IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v64y2003i1p75-88.html
   My bibliography  Save this article

Stimulating pharmaceutical research and development for neglected diseases

Author

Listed:
  • Mrazek, Monique F.
  • Mossialos, Elias

Abstract

No abstract is available for this item.

Suggested Citation

  • Mrazek, Monique F. & Mossialos, Elias, 2003. "Stimulating pharmaceutical research and development for neglected diseases," Health Policy, Elsevier, vol. 64(1), pages 75-88, April.
    • Handle: RePEc:eee:hepoli:v:64:y:2003:i:1:p:75-88
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(02)00138-0
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Michael Kremer, 2001. "Creating Markets for New Vaccines - Part II: Design Issues," NBER Chapters, in: Innovation Policy and the Economy, Volume 1, pages 73-118, National Bureau of Economic Research, Inc.
    2. Alan Williams, 2001. "Science or marketing at WHO? A commentary on ‘World Health 2000’," Health Economics, John Wiley & Sons, Ltd., vol. 10(2), pages 93-100, March.
    3. Michael Kremer, 2001. "Creating Markets for New Vaccines - Part I: Rationale," NBER Chapters, in: Innovation Policy and the Economy, Volume 1, pages 35-72, National Bureau of Economic Research, Inc.
    4. Lanjouw, Jean O. & Cockburn, Iain M., 2001. "New Pills for Poor People? Empirical Evidence after GATT," World Development, Elsevier, vol. 29(2), pages 265-289, February.
    5. Sievers, Allen M., 2000. "The indonesian economy, second edition1," Journal of Asian Economics, Elsevier, vol. 11(3), pages 359-362, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Mueller-Langer, Frank, 2011. "Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting research?," MPRA Paper 40193, University Library of Munich, Germany.
    2. Forman, Rebecca & Azzopardi-Muscat, Natasha & Kirkby, Victoria & Lessof, Suszy & Nathan, Naomi Limaro & Pastorino, Gabriele & Permanand, Govin & van Schalkwyk, May CI & Torbica, Aleksandra & Busse, Re, 2022. "Drawing light from the pandemic: Rethinking strategies for health policy and beyond," Health Policy, Elsevier, vol. 126(1), pages 1-6.
    3. Aerts, Céline & Sunyoto, Temmy & Tediosi, Fabrizio & Sicuri, Elisa, 2017. "Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature," Health Policy, Elsevier, vol. 121(7), pages 745-754.
    4. Claudimar Pereira Da Veiga & Cássia Rita Pereira Da Veiga & Jansen Maia Del Corso & Wesley Vieira Da Silva, 2015. "Dengue Vaccines: A Perspective from the Point of View of Intellectual Property," IJERPH, MDPI, vol. 12(8), pages 1-21, August.
    5. Veiga, Cássia Rita Pereira da & da Veiga, Claudimar Pereira & Mamédio, Diórgenes Falcão & Su, Zhaohui, 2024. "Innovative advances for neglected tropical disease (NTD): A global perspective from intellectual property," Technology in Society, Elsevier, vol. 78(C).
    6. Driouchi, Ahmed, 2015. "New Health Technologies and Health Workforce in Developing Economies," MPRA Paper 67775, University Library of Munich, Germany.
    7. Munira, Syarifah Liza & Fritzen, Scott A., 2007. "What influences government adoption of vaccines in developing countries? A policy process analysis," Social Science & Medicine, Elsevier, vol. 65(8), pages 1751-1764, October.
    8. Mueller-Langer, Frank, 2013. "Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?," Health Economics, Policy and Law, Cambridge University Press, vol. 8(2), pages 185-208, April.
    9. Charnele Nunes & Martin McKee & Natasha Howard, 2024. "The role of global health partnerships in vaccine equity: A scoping review," PLOS Global Public Health, Public Library of Science, vol. 4(2), pages 1-16, February.
    10. Srinivas, Smita, 2006. "Industrial Development and Innovation: Some Lessons from Vaccine Procurement," World Development, Elsevier, vol. 34(10), pages 1742-1764, October.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jean O. Lanjouw, 2003. "Intellectual Property and the Availability of Pharmaceuticals in Poor Countries," NBER Chapters, in: Innovation Policy and the Economy, Volume 3, pages 91-130, National Bureau of Economic Research, Inc.
    2. de Walque, Damien, 2007. "How does the impact of an HIV/AIDS information campaign vary with educational attainment? Evidence from rural Uganda," Journal of Development Economics, Elsevier, vol. 84(2), pages 686-714, November.
    3. Ben van Hout & Jolian McHardy & Aki Tsuchiya, 2015. "Patent Purchase as a Policy for Pharmaceuticals," Working Papers 2015007, The University of Sheffield, Department of Economics.
    4. Czarnitzki, Dirk & Toole, Andrew A., 2006. "Business R&D and the Interplay of R&D Subsidies and Market Uncertainty," ZEW Discussion Papers 06-055, ZEW - Leibniz Centre for European Economic Research.
    5. Michael Kremer & Christopher M. Snyder, 2003. "Why Are Drugs More Profitable Than Vaccines?," NBER Working Papers 9833, National Bureau of Economic Research, Inc.
    6. Lakdawalla, Darius & Sood, Neeraj, 2009. "Innovation and the welfare effects of public drug insurance," Journal of Public Economics, Elsevier, vol. 93(3-4), pages 541-548, April.
    7. Reto Foellmi & Josef Zweimuller, 2006. "Income Distribution and Demand-Induced Innovations," The Review of Economic Studies, Review of Economic Studies Ltd, vol. 73(4), pages 941-960.
    8. Christine Greenhalgh & Padraig Dixon, 2002. "The Economics of Intellectual Property: A Review to Identify Themes for Future Research," Economics Series Working Papers 135, University of Oxford, Department of Economics.
    9. Agarwal, Ruchir & Gaule, Patrick, 2022. "What drives innovation? Lessons from COVID-19 R&D," Journal of Health Economics, Elsevier, vol. 82(C).
    10. Ahlvik, Lassi & van den Bijgaart, Inge, 2024. "Screening green innovation through carbon pricing," Journal of Environmental Economics and Management, Elsevier, vol. 124(C).
    11. Dirk Czarnitzki & Andrew Toole, 2007. "Business R&D and the Interplay of R&D Subsidies and Product Market Uncertainty," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 31(3), pages 169-181, November.
    12. Acharyya, Rajat & Garcia-Alonso, Maria D.C., 2006. "Self-interested international income redistribution and access to health care innovation," European Journal of Political Economy, Elsevier, vol. 22(2), pages 322-336, June.
    13. Lakdawalla, Darius & Sood, Neeraj, 2004. "Social insurance and the design of innovation incentives," Economics Letters, Elsevier, vol. 85(1), pages 57-61, October.
    14. Casey B. Mulligan, 2021. "Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation," NBER Working Papers 29574, National Bureau of Economic Research, Inc.
    15. Bardhan, Pranab, 2005. "Law and Economics in the Tropics: Some Reflections," International Review of Law and Economics, Elsevier, vol. 25(1), pages 65-74, March.
    16. Fu, Qiang & Lu, Jingfeng & Lu, Yuanzhu, 2012. "Incentivizing R&D: Prize or subsidies?," International Journal of Industrial Organization, Elsevier, vol. 30(1), pages 67-79.
    17. Ze Chen & Bingzheng Chen & Yu Mao, 2024. "Fence off Black Swans: The Economics of Insurance for Vaccine Injury," Oxford Bulletin of Economics and Statistics, Department of Economics, University of Oxford, vol. 86(5), pages 995-1025, October.
    18. Ernst R. Berndt, 2002. "Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 45-66, Fall.
    19. Jorge Marshall R., 2002. "El Camino de las Reformas," Notas de Investigación Journal Economía Chilena (The Chilean Economy), Central Bank of Chile, vol. 5(1), pages 77-82, April.
    20. Xavier Sala-i-Martin, 2002. "15 Years of New Growth Economics : What Have we Learnt?," Journal Economía Chilena (The Chilean Economy), Central Bank of Chile, vol. 5(2), pages 5-15, August.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:64:y:2003:i:1:p:75-88. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.